Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

JAMA oncology·2026

Same author

Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment.

Immunity·2026

Same author

Influence of Tumor-Draining Lymph Nodes on Immunotherapy: Lymphadenectomy May Have Its Limits.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer.

Cellular and molecular gastroenterology and hepatology·2026

Same author

Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma.

Science (New York, N.Y.)·2026

Same author

KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We Have All Been Waiting for.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Search research articles

Related Experiment Video

Updated: May 9, 2026

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

CD40 therapy and surgery: a potential immunologic partnership

Katelyn T Byrne¹, Robert H Vonderheide

¹Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Journal of Immunotherapy (Hagerstown, Md. : 1997)

|August 9, 2013

Summary

No abstract available in PubMed .

More Related Videos

Generation of Human CD40-activated B cells

Generation of Human CD40-activated B cells

Published on: October 16, 2009

Related Experiment Videos

Last Updated: May 9, 2026

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Generation of Human CD40-activated B cells

Generation of Human CD40-activated B cells

Published on: October 16, 2009